George Hripcsak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8456855/publications.pdf

Version: 2024-02-01

95 papers 6,214 citations

34 h-index 79698 73 g-index

104 all docs

104 docs citations

times ranked

104

12216 citing authors

#	Article	IF	CITATIONS
1	Letter to the editor: vaccination against upper respiratory infections is a matter of survival in alcoholic liver disease. Gut, 2023, 72, 208-209.	12.1	1
2	Leveraging electronic health record data for clinical trial planning by assessing eligibility criteria's impact on patient count and safety. Journal of Biomedical Informatics, 2022, 127, 104032.	4.3	1
3	Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study. Circulation, 2022, 145, 877-891.	1.6	18
4	Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. Clinical Epidemiology, 2022, Volume 14, 369-384.	3.0	11
5	Patient characteristics and antiseizure medication pathways in newly diagnosed epilepsy: Feasibility and pilot results using the common data model in a single-center electronic medical record database. Epilepsy and Behavior, 2022, 129, 108630.	1.7	4
6	Factors Influencing Background Incidence Rate Calculation: Systematic Empirical Evaluation Across an International Network of Observational Databases. Frontiers in Pharmacology, 2022, 13, 814198.	3.5	8
7	Characterizing Anchoring Bias in Vaccine Comparator Selection Due to Health Care Utilization With COVID-19 and Influenza: Observational Cohort Study. JMIR Public Health and Surveillance, 2022, 8, e33099.	2.6	2
8	Delay-induced uncertainty for a paradigmatic glucose–insulin model. Chaos, 2021, 31, 023142.	2.5	7
9	Implementation of the COVID-19 Vulnerability Index Across an International Network of Health Care Data Sets: Collaborative External Validation Study. JMIR Medical Informatics, 2021, 9, e21547.	2.6	11
10	Comprehensive Comparative Effectiveness and Safety of First-Line \hat{l}^2 -Blocker Monotherapy in Hypertensive Patients. Hypertension, 2021, 77, 1528-1538.	2.7	20
11	Characterising the long-term clinical outcomes of 1190 hospitalised patients with COVID-19 in New York City: a retrospective case series. BMJ Open, 2021, 11, e049488.	1.9	19
12	Clinical comparison between trial participants and potentially eligible patients using electronic health record data: A generalizability assessment method. Journal of Biomedical Informatics, 2021, 119, 103822.	4.3	8
13	Data Consult Service: Can we use observational data to address immediate clinical needs?. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 2139-2146.	4.4	3
14	Generalizability of Polygenic Risk Scores for Breast Cancer Among Women With European, African, and Latinx Ancestry. JAMA Network Open, 2021, 4, e2119084.	5.9	31
15	Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension, 2021, 78, 591-603.	2.7	63
16	Columbia Open Health Data for COVID-19 Research: Database Analysis. Journal of Medical Internet Research, 2021, 23, e31122.	4.3	3
17	Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology, 2021, 60, 3222-3234.	1.9	20
18	Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study. BMJ Open, 2021, 11, e057632.	1.9	8

#	Article	IF	CITATIONS
19	Adapting electronic health records-derived phenotypes to claims data: Lessons learned in using limited clinical data for phenotyping. Journal of Biomedical Informatics, 2020, 102, 103363.	4.3	13
20	Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nature Communications, 2020, 11, 5009.	12.8	86
21	Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1268-1277.	4.4	19
22	Characterizing physicians' information needs related to a gap in knowledge unmet by current evidence. JAMIA Open, 2020, 3, 281-289.	2.0	8
23	Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND). Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1331-1337.	4.4	31
24	The Prognostic Value of Electrocardiogram at Presentation to Emergency Department in Patients With COVID-19. Mayo Clinic Proceedings, 2020, 95, 2099-2109.	3.0	43
25	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatology, The, 2020, 2, e698-e711.	3.9	117
26	A scoping review of clinical decision support tools that generate new knowledge to support decision making in real time. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1968-1976.	4.4	18
27	Application of Epidemiological Geographic Information System: An Open-Source Spatial Analysis Tool Based on the OMOP Common Data Model. International Journal of Environmental Research and Public Health, 2020, 17, 7824.	2.6	4
28	Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 382, 2411-2418.	27.0	1,351
29	Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ, The, 2020, 369, m1996.	6.0	588
30	Treatment Patterns for Chronic Comorbid Conditions in Patients With Cancer Using a Large-Scale Observational Data Network. JCO Clinical Cancer Informatics, 2020, 4, 171-183.	2.1	14
31	Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertensionâ€"Reply. JAMA Internal Medicine, 2020, 180, 1133.	5.1	1
32	Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Internal Medicine, 2020, 180, 542.	5.1	97
33	How Confident Are We About Observational Findings in Health Care: A Benchmark Study. , 2020, 2, .		32
34	Comparison of First-Line Dual Combination Treatments in Hypertension: Real-World Evidence from Multinational Heterogeneous Cohorts. Korean Circulation Journal, 2020, 50, 52.	1.9	19
35	A plea to stop using the caseâ€control design in retrospective database studies. Statistics in Medicine, 2019, 38, 4199-4208.	1.6	42
36	Facilitating phenotype transfer using a common data model. Journal of Biomedical Informatics, 2019, 96, 103253.	4.3	49

3

#	Article	IF	Citations
37	Making work visible for electronic phenotype implementation: Lessons learned from the eMERGE network. Journal of Biomedical Informatics, 2019, 99, 103293.	4.3	27
38	Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet, The, 2019, 394, 1816-1826.	13.7	228
39	Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. American Journal of Human Genetics, 2019, 105, 588-605.	6.2	99
40	Network Analysis of Citation in Hypertension Clinical Guidelines. Studies in Health Technology and Informatics, 2019, 264, 1017-1020.	0.3	4
41	Origins of the Arden Syntax. Artificial Intelligence in Medicine, 2018, 92, 7-9.	6.5	8
42	Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2571-2577.	7.1	91
43	Mechanistic machine learning: how data assimilation leverages physiologic knowledge using Bayesian inference to forecast the future, infer the present, and phenotype. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1392-1401.	4.4	30
44	Methodological variations in lagged regression for detecting physiologic drug effects in EHR data. Journal of Biomedical Informatics, 2018, 86, 149-159.	4.3	14
45	Improving reproducibility by using high-throughput observational studies with empirical calibration. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2018, 376, 20170356.	3.4	53
46	Disease Heritability Inferred from Familial Relationships Reported in Medical Records. Cell, 2018, 173, 1692-1704.e11.	28.9	79
47	Association of Hemoglobin A _{1c} Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin. JAMA Network Open, 2018, 1, e181755.	5.9	54
48	High-fidelity phenotyping: richness and freedom from bias. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 289-294.	4.4	56
49	Columbia Open Health Data, clinical concept prevalence and co-occurrence from electronic health records. Scientific Data, 2018, 5, 180273.	5.3	41
50	New insights into highly potent tyrosinase inhibitors based on 3-heteroarylcoumarins: Anti-melanogenesis and antioxidant activities, and computational molecular modeling studies. Bioorganic and Medicinal Chemistry, 2017, 25, 1687-1695.	3.0	53
51	MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study, and docking calculations. MedChemComm, 2017, 8, 1788-1796.	3.4	17
52	Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. Epilepsia, 2017, 58, e101-e106.	5.1	37
53	Personalized glucose forecasting for type 2 diabetes using data assimilation. PLoS Computational Biology, 2017, 13, e1005232.	3.2	74
54	Leveraging 3D chemical similarity, target and phenotypic data in the identification of drug-protein and drug-adverse effect associations. Journal of Cheminformatics, 2016, 8, 35.	6.1	10

#	Article	IF	Citations
55	Discovery of the first A ₁ adenosine receptor ligand based on the chromone scaffold. RSC Advances, 2016, 6, 46972-46976.	3.6	4
56	Robust empirical calibration of <i>p</i> â€values using observational data. Statistics in Medicine, 2016, 35, 3883-3888.	1.6	43
57	Computational Drug Target Screening through Protein Interaction Profiles. Scientific Reports, 2016, 6, 36969.	3.3	9
58	Characterizing treatment pathways at scale using the OHDSI network. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7329-7336.	7.1	256
59	Preserving temporal relations in clinical data while maintaining privacy. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 1040-1045.	4.4	17
60	Progress in the development of small molecules as new human A ₃ adenosine receptor ligands based on the 3-thiophenylcoumarin core. MedChemComm, 2016, 7, 845-852.	3.4	4
61	Feasibility of Prioritizing Drug–Drug-Event Associations Found in Electronic Health Records. Drug Safety, 2016, 39, 45-57.	3.2	31
62	Participatory approach to the development of a knowledge base for problem-solving in diabetes self-management. International Journal of Medical Informatics, 2016, 85, 96-103.	3.3	23
63	Development of novel adenosine receptor ligands based on the 3-amidocoumarin scaffold. Bioorganic Chemistry, 2015, 61, 1-6.	4.1	9
64	Intercepting Wrong-Patient Orders in a Computerized Provider Order Entry System. Annals of Emergency Medicine, 2015, 65, 679-686.e1.	0.6	36
65	Potent and selective MAO-B inhibitory activity: Amino- versus nitro-3-arylcoumarin derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 642-648.	2.2	28
66	3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance. Scientific Reports, 2015, 5, 8809.	3.3	18
67	Parameterizing time in electronic health record studies. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 794-804.	4.4	51
68	Design and discovery of tyrosinase inhibitors based on a coumarin scaffold. RSC Advances, 2015, 5, 94227-94235.	3.6	48
69	Navigating in chromone chemical space: discovery of novel and distinct A ₃ adenosine receptor ligands. RSC Advances, 2015, 5, 78572-78585.	3.6	11
70	Practical considerations in genomic decision support: The eMERGE experience. Journal of Pathology Informatics, 2015, 6, 50.	1.7	42
71	Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Studies in Health Technology and Informatics, 2015, 216, 574-8.	0.3	533
72	Similarity-based modeling in large-scale prediction of drug-drug interactions. Nature Protocols, 2014, 9, 2147-2163.	12.0	178

#	Article	IF	CITATIONS
73	Development and validation of an electronic phenotyping algorithm for chronic kidney disease. AMIA Annual Symposium proceedings, 2014, 2014, 907-16.	0.2	31
74	Nonconvulsive seizures after subarachnoid hemorrhage: Multimodal detection and outcomes. Annals of Neurology, 2013, 74, 53-64.	5. 3	162
75	Visualizing the operating range of a classification system. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 529-532.	4.4	4
76	Population Physiology: Leveraging Electronic Health Record Data to Understand Human Endocrine Dynamics. PLoS ONE, 2012, 7, e48058.	2.5	22
77	Use of electronic clinical documentation: time spent and team interactions. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 112-117.	4.4	132
78	Using the Federated Council for Internal Medicine Curricular Guide and Administrative Codes to Assess IM Residents' Breadth of Experience. Academic Medicine, 2004, 79, 557-563.	1.6	3
79	Use of Natural Language Processing to Translate Clinical Information from a Database of 889,921 Chest Radiographic Reports. Radiology, 2002, 224, 157-163.	7.3	174
80	Reference Standards, Judges, and Comparison Subjects: Roles for Experts in Evaluating System Performance. Journal of the American Medical Informatics Association: JAMIA, 2002, 9, 1-15.	4.4	65
81	WebCIS: large scale deployment of a Web-based clinical information system. Proceedings, 1999, , 804-8.	0.6	55
82	Extracting findings from narrative reports: software transferability and sources of physician disagreement. Methods of Information in Medicine, 1998, 37, 1-7.	1.2	33
83	Automated Tuberculosis Detection. Journal of the American Medical Informatics Association: JAMIA, 1997, 4, 376-381.	4.4	42
84	IAIMS architecture. Journal of the American Medical Informatics Association: JAMIA, 1997, 4, S20-30.	4.4	8
85	Access to Data: Comparing AccessMed With Query by Review. Journal of the American Medical Informatics Association: JAMIA, 1996, 3, 288-299.	4.4	26
86	Natural language processing in an operational clinical information system. Natural Language Engineering, 1995, 1, 83-108.	2. 5	79
87	User comments on a clinical event monitor. Proceedings, 1994, , 636-40.	0.4	3
88	The arden syntax for medical logic modules. Journal of Clinical Monitoring and Computing, 1993, 10, 215-224.	0.3	70
89	Desperately seeking data: knowledge base-database links. Proceedings, 1993, , 639-43.	0.4	7
90	ASTM E31.15 on health knowledge representation: the Arden Syntax. Studies in Health Technology and Informatics, 1993, 6, 105-12.	0.3	7

#	Article	IF	CITATIONS
91	The Columbia-Presbyterian Medical Center decision-support system as a model for implementing the Arden Syntax. Proceedings, 1991, , 248-52.	0.4	13
92	Arden Syntax for Medical Logic Modules. M D Computing, 1991, 8, 76, 78.	0.1	21
93	Using connectionist modules for decision support. Methods of Information in Medicine, 1990, 29, 167-81.	1.2	1
94	Web-based monitoring of asthma severity: a new approach to ambulatory management. , 0, , .		10
95	Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ, The, 0, , n1435.	6.0	112